Endoscopy-related infections and toxic reactions: an international comparison

This article is an analysis of the characteristics of exogenous endoscopy-related infections, pseudoinfections, and toxic reactions that have occurred worldwide during the period 1974 - 2004. A systematic review of the scientific literature published between 1966 and 2004 was conducted in Medline and the Food and Drug Administration Reports database, using a prospective protocol developed by the authors. The literature review identified 140 outbreaks, reported in 134 scientific articles. More than 94 % of the outbreaks identified could have been prevented by improved decontamination processes. Proper decontamination practices and the improvement of surveillance systems could reduce the clinical burden associated with exogenous endoscopy-related events.

References

• 1 Muscarella L F. Dear Los Angeles Times: the risk of disease transmission during gastrointestinal endoscopy.  Gastroenterol Nurs. 2004;  27 271-278
• 2 Nelson D B. Infection control during gastrointestinal endoscopy.  J Lab Clin Med. 2003;  141 159-167
• 3 Cronmiller J R, Nelson D K, Salman G. et al . Antimicrobial efficacy of endoscopic disinfection procedures: a controlled, multifactorial investigation.  Gastrointest Endosc. 1999;  50 152-158
• 4 Foliente R L, Kovacs B J, Aprecio R M. et al . Efficacy of high-level disinfectants for reprocessing gastrointestinal endoscopes in simulated-use testing.  Gastrointest Endosc. 2001;  53 456-462
• 5 Spach D H, Silverstein F E, Stamm W E. Transmission of infection by gastrointestinal endoscopy and bronchoscopy.  Ann Intern Med. 1993;  118 117-128
• 6 Prakash U B. Does the bronchoscope propagate infection?.  Chest. 1993;  104 552-559
• 7 Nelson D B. Infectious disease complications of GI endoscopy: part I, endogenous infections.  Gastrointest Endosc. 2003;  57 546-556
• 8 Vennes J A. Infectious complications of gastrointestinal endoscopy.  Dig Dis Sci. 1981;  26 (7 Suppl) 60S-64S
• 9 Favero M S. Strategies for disinfection and sterilization of endoscopes: the gap between basic principles and actual practice.  Infect Control Hosp Epidemiol. 1991;  12 279-281
• 10 Axon A T. Working Party Report to the World Congresses. Disinfection and endoscopy: summary and recommendations.  J Gastroenterol Hepatol. 1991;  6 23-24
• 11 Pajkos A, Vickery K, Cossart Y. Is biofilm accumulation on endoscope tubing a contributor to the failure of cleaning and decontamination?.  J Hosp Infect. 2004;  58 224-229
• 12 Tunuguntla A, Sullivan M J. Monitoring quality of flexible endoscope disinfection by microbiologic surveillance cultures.  Tenn Med. 2004;  97 453-456
• 13 Aanstoos C M. Endoscopes: clean clear through?.  Am J Nurs. 1992;  92 14
• 14 Urayama S, Kozarek R A, Sumida S. et al . Mycobacteria and glutaraldehyde: is high-level disinfection of endoscopes possible?.  Gastrointest Endosc. 1996;  43 451-456
• 15 Vesley D, Melson J, Stanley P. Microbial bioburden in endoscope reprocessing and an in-use evaluation of the high-level disinfection capabilities of Cidex PA.  Gastroenterol Nurs. 1999;  22 63-68
• 16 Nelson D B. Infectious disease complications of GI endoscopy: part II, exogenous infections.  Gastrointest Endosc. 2003;  57 695-711
• 17 Gorse G J, Messner R L. Infection control practices in gastrointestinal endoscopy in the United States: a national survey.  Gastroenterol Nurs. 1991;  14 72-79
• 18 Seoane-Vazquez E, Rodriguez-Monguio R, Visaria J. et al . Exogenous endoscopy-related infections, pseudo-infections, and toxic reactions: clinical and economic burden.  Curr Med Res Opin. 2006;  22 2007-2021
• 19 Alvarado C J, Reichelderfer M. APIC guideline for infection prevention and control in flexible endoscopy. Association for Professionals in Infection Control.  Am J Infect Control. 2000;  28 138-155
• 20 Food and Drug Administration .Manufacturer and User Facility Device Experience Database (MAUDE). Food and Drug Administration, 2005 [accessed 2005, July 20]. http://www.fda.gov/cdrh/maude.html
• 21 Food and Drug Administration .Medical Device Reporting (MDR): General Information. Food and Drug Administration, 2002 [accessed 2005, July 20]. http://www.fda.gov/cdrh/mdr/mdr-general.html
• 22 Food and Drug Administration .FDA Enforcement Report Index 2005 [accessed 2005, July 20]. http://www.fda.gov/opacom/Enforce.html
• 23 Lautenbach E, Woeltje K (eds). Practical handbook for healthcare epidemiologists, 2nd edn. Thorofare, New Jersey; Slack Inc 2004
• 24 Manzoor S E, Lambert P A, Griffiths P A. et al . Reduced glutaraldehyde susceptibility in Mycobacterium chelonae associated with altered cell wall polysaccharides.  J Antimicrob Chemother. 1999;  43 759-765
• 25 Archibald L, Phillips L, Monnet D. et al . Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit.  Clin Infect Dis. 1997;  24 211-215
• 26 Ward M M, Diekema D J, Yankey J W. et al . Implementation of strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in U.S. hospitals.  Infect Control Hosp Epidemiol. 2005;  26 21-30
• 27 Goldmann D A, Weinstein R A, Wenzel R P. et al . Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership.  JAMA. 1996;  275 234-240